Onkodisruptor Electroporator



The Electroporator, designated as Onkodisruptor®, is a state of the art of the electrochemotherapy ECT  apparatus which is the evolution of the electroporators successfully used by our group over the past ten years. The characteristics of the train of permeabilizing waveforms, as well as the configuration of the novel electrodes specifically developed for this equipment, make the Onkodisruptor® a unique product. Regarding the unique features of our product we state that the novel pulses are 2 times faster than the previously developed electroporation systems and cause 2 times less discomfort to the animal.

The Electroporator generates a train of 8 biphasic pulses that have been stabilized by a dedicated software program. Such pulses have an interpulse of 10 microseconds and have a 50+50 microseconds duration. The instrument voltage goes from 100 up to 1500 volts and is regulated by the operator. An acoustic signal is generated each time the apparatus successfully discharges the train of pulses and there is a safety switch that triggers an autodischarge program if the impulses are not delivered within 30 seconds.

Biopulse  is the sole source of such equipment specifically developed for Veterinary profession. Onkodisruptor® has been purchased from many specialized veterinary clinics and universities around the world.

The possibility of delivering traditional drugs and new synthetic molecules through equipment which facilitates the specific uptake by the tumor cells, will allow for a signifcant reduction of unwanted side effects, while maintaining, or even increasing, the pharmacological efficacy.

Onkodisruptor Electroporator Full Set

Electroporator Onkodisruptor® conforms EU certifications: EN 60950/55011/61000-6-1/61000-6-3

Company Updates

  • June 14 2018 ACVIM Forum. The Oncology Italian Research at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum. Dr. Spugnini’s conferences will explore new therapeutic frontiers in veterinary oncology field during the most important veterinary event in Seattle.
  • August 10 2017 First Onkodisruptor study on Humans (blog article here)  : Succesful treatment of plantar warts with intralesional bleomicin and electroporation: Pilot prospective study.
  • Dec 20 2017 About us on the Magazine The HorseVeterinarians Test New Hoof Cancer Treatment. After surgically debulking the tumor, veterinarians administered electrochemotherapy directly into the cancer site. Article.
  • July 31  2017 New article about : Treatment of an advanced squamous cell carcinoma of the hoof in a mare.
  • March 08 2017 New Blog post about one recent Onkodisruptor application :Ultrasound guided electrochemotherapy for the treatment of a c-lear cell thymoma in a cat
  • February 03 2017 New Blog post about one recent Onkodisruptor application :Surgery and electrochemotherapy treatment of incompletely excised mammary carcinoma.
  • Dec 20 2016 New Blog post about one recent Onkodisruptor application : Salvage electrochemotherapy in a stallion with recurring penile fibrosarcoma
  • June 13 2016 New Blog post about one recent Onkodisruptor application.
  • June 10 2016 Check out the new publications page.
  • May 15 2015 The new needles are in the test phase.
  • June 08 2014 A new article was published on Journal of Cell Physiology
  • November 15 2014 A new article was published on Journal of Equine Veterinary Science

Biopulse will be present at these conferences :

  • 2018 ACVIM Forum The Oncology Italian Research at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum with Dr. Enrico Pierluigi Spugnini. Article.
  • DUBAI MED LAB Feb 2018. We was guests at the stand of DAS italy.
  • Dr Spugnini will be present as Speaker at the European Society of Veterinary Oncology Annual Congress in Lyon .From 20th to 22nd April 2017.
  • DUBAI MED LAB 2017 6-9 Feb 2017. We will be guests at the stand of DAS italy – Hall Z6 number C59. Article.
  • WORKSHOP ELECTROCHEMOTHERAPY BRASIL I Workshop on Electrochemotherapy, Ribeirão Preto- SP. NOVEMBER 9-10 2016 University of Franca (UNIFRAN).With Dr. Enrico Pierluigi Spugnini.

Electroporation News

Onkodisruptor Electroporator : The first study on the treatment of human cancer.

Successful Treatment of a Keratoacanthoma with Electrochemotherapy: A Case Report of human skin cancer We report the first study on the treatment of human cancer with Onkodisruptor Keratoacanthoma in an 86-year-old patient was treated with intralesional bleomycin combined with electroporation. Treatment consisted of local application of shorty and intense electric pulses followed by local injection of bleomycin. Electroporation was always well tolerated

About us on the Magazine The Horse.com

Electrochemotherapy for equine veterinary medicine In the past 10 years, the clinical efficacy of the therapeutic approach of the Electrochemotherapy in several models of tumors in animals has been shown. Our goal is improve the quality of animals' life. “In terms of welfare, it has been well worth the treatment the mare went through. And since there’s such a severe lack

Why Choose Us

  • Our equipments are manufactured with the highest quality standards.

  • We assist our clients step by step providing technical and scientific support 24h/7d.

  • Our customers have a very high satisfaction rate and a short ROI.
  • We support ethical treatment of animals and our studies are completely cruelty free.
  • Electroporator Onkodisruptor® is unique and there are no other electroporators on the market with the same characteristics and Scientific Results.

  • Our partner and and manufacturer DAS is a certified company UNIEN ISO 9001 and UNIEN ISO 13485.

Electroporator Quality Standards

Beware of imitations, many products on the market as well as not producing any scientific and clinical outcome can be dangerous for patients and operators.

Onkodisruptor is the undisputed leader in the veterinary field with a vast scientific production and an unrivaled customer satisfaction.

Our Clients and Friends